Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies
Open Access
- 11 October 2019
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
Abstract
Background: Enteric fever is an acute febrile-illness caused by infection with the human-restricted Salmonella serovars Typhi and Paratyphi. Controlled human infection models (CHIM) of S. Typhi and Paratyphi infection are used to accelerate vaccine development and to better understand host-pathogen interactions. The primary motivations for participants to take part in these studies are unknown. We studied participant motivations, attitudes and the factors influencing CHIM study participation. Methods: Participant surveys were nested in six enteric fever CHIM studies conducted at a single centre in Oxford, UK, between 2011 and 2017. All eligible participants received one invitation to complete an anonymous, self-administered paper or online survey on either day 28 or 60 after challenge. A descriptive analysis was performed on these pooled data. All studies were included, to minimize selection bias. Results: Survey response rates varied from 33.0%-86.1%, yielding 201 participants. In the cohort, 113/198(57.0%) were educated to bachelor’s level, 61.6% were employed, 30.3% were students and 4.6% were unemployed. The most commonly cited motivations for CHIM study participation were a desire to contribute to the progression of medicine (170/201; 84.6%); the prospect of financial reimbursement (166/201; 82.6%) and curiosity about clinical trials (117/201; 57.2%). The majority of respondents (139/197; 70.6%) reported that most people advised them against participation. Conclusion: Motivation to participate in a CHIM study was multi-factorial and heavily influenced by internal drivers beyond monetary reimbursement alone. High educational attainment and employment may be protective factors against financial inducement; however, further research is needed, particularly with CHIM studies expanding to low-income and middle-income countries.Funding Information
- Medical Research Council (MR/K021222/1)
- Bill and Melinda Gates Foundation (OPP1126235, OPP1084259)
- Wellcome Trust (092661)
- Seventh Framework Programme
- National Institutes of Health (U19 AI-082655, R01AI-036525)
- National Institute for Health Research
- National Institutes of Health (U19 AI-082655, R01AI-036525)
- European Vaccine Initiative
This publication has 20 references indexed in Scilit:
- The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Infectious Diseases, 2019
- Extensively Drug-Resistant Typhoid — Are Conjugate Vaccines Arriving Just in Time?The New England Journal of Medicine, 2018
- Vaccines for preventing typhoid feverEmergencias, 2018
- Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trialThe Lancet, 2017
- Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge ModelClinical Infectious Diseases, 2017
- Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21aPLoS Neglected Tropical Diseases, 2016
- Status of paratyphoid fever vaccine research and developmentVaccine, 2016
- Ethical Criteria for Human Challenge Studies in Infectious Diseases: Table 1.Public Health Ethics, 2015
- Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectorsVaccine, 2003
- Host–Salmonella interaction: human trialsMicrobes and Infection, 2001